Alpha Tau Medical Ltd. (DRTS)

NASDAQ: DRTS · USD

$13.4

-0.10 (-0.7%)· Recorded snapshot

Market cap	1.2B
Net income (ttm)	-92.6M
EPS (ttm)	-$1.05
Shares out	92.3M
Volume	368,597
Beta	1.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -92.6M
EPS (ttm): -$1.05
Market cap: 1.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-141.7

P25 n/aP50 n/aP75 n/a

ROIC-39.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DRTS indicators

Market & fundamental data

Available fields

179

Groups with data

Currency

USD

Showing 179 of 179 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001871321
Company name	Alpha Tau Medical Ltd.
Country	Israel
Country code	US
CUSIP number	M0740A108
Earnings date	2026-11-19
Earnings time	amc
Employees	121
Employees change	-4
Employees growth	-3.2%
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	IL0011839383
Last 10-K release date	2026-03-09
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.2B
Market cap category	Small-Cap
Next earnings date	2026-11-19
Options	Yes
Price	$13.41
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	DRTS
Website	https://www.alphatau.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-7.84%
FCF / EV yield	-1.39%
FCF yield	-1.29%
Forward EV/Sales	321.03x
Forward P/S	344.65x
P/B ratio	28.32x
Price / tangible book value	28.32x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-765,074
ROA	-25.71%
ROA (5Y)	-22.65%
ROCE	-40.47%
ROE	-141.68%
ROE (5Y)	-48.67%
ROIC	-39.61%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3.3M
Depreciation and amortization	$1.7M
EBIT	$-50.4M
EBITDA	$-48.8M
EPS	$-1.05
FCF per share	$-0.17
Financing cash flow	$38M
Free cash flow	$-16.1M
Free cash flow minus SBC	$-28.1M
Income taxes	$175,000
Investing cash flow	$-13.8M
Net cash flow	$11.3M
Net income	$-92.6M
Operating cash flow minus SBC	$-24.8M
Operating income	$-50.4M
Stock-based compensation	$12M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.48
Debt / equity	0.34
Interest coverage	-140.08
Long-term assets	$27.4M
Long-term liabilities	$80.6M
Net cash (debt)	$85.5M
Net cash / market cap	6.85%
Net cash growth	28.77%
Net debt / equity	-1.94
Piotroski F-Score	2
Property, plant and equipment	$26.9M
Shareholders' equity	$44.1M
Tangible book value	$44.1M
Tangible book value per share	$0.48
Total assets	$134.3M
Total cash	$100.6M
Total debt	$15.2M
Total liabilities	$90.2M
WACC	10.87%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$106.8M
Current liabilities	$9.6M
Current ratio	11.09
Net working capital	$-2.1M
Quick ratio	10.45
Working capital	$97.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-20.98%
Dividend yield	0%
Shareholder yield	-20.98%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$11.64
1D price change	-0.74%
1M price change	-8.05%
1M total return	-8.05%
1W price change	2.14%
1W total return	2.14%
1Y price change	221.39%
1Y return CAGR	221.65%
1Y total return	221.39%
20-day SMA	$13.66
200-day SMA	$10.54
3M price change	9.5%
3M total return	9.5%
3Y price change	305.15%
3Y return CAGR	59.4%
3Y total return	305.15%
50-day SMA	$14.31
50-day SMA vs 200-day SMA	50over200
52-week high	$15.79
52-week high date	2026-09-17
52-week low	$3.43
52-week low date	2025-11-21
5Y price change	34.64%
5Y return CAGR	6.13%
5Y total return	34.64%
6M price change	69.03%
6M total return	69.03%
All-time high	$20.65
All-time high date	2022-03-24
All-time low	$1.75
All-time low date	2024-06-27
Average true range (ATR)	$0.65
Average volume	464.9K
Beta (1Y)	1.73
Beta (2Y)	1.04
Beta (5Y)	1.22
Change from 52-week high	-15.07%
Change from 52-week low	290.96%
Change from all-time high	-35.25%
Change from all-time low	664%
Change from open	-0.67%
Day's gap	-0.07%
Dollar volume	$4.9M
High price	$13.60
Low price	$13.30
Monthly RSI	72.5
Open price	$13.50
Position in 52-week range	36.67%
Premarket change	-1.04%
Premarket close	$13.51
Premarket price	$13.37
Premarket volume	993
Previous close	$13.51
Price vs 150-day SMA	14.84%
Price vs 20-day SMA	-2.15%
Price vs 200-day SMA	26.9%
Price vs 50-day SMA	-6.57%
Relative volume	0.79
RSI	46.25
Sharpe ratio	1.84
Sharpe ratio (3Y)	0.98
Sharpe ratio (5Y)	0.41
Sortino ratio	3.38
Sortino ratio (3Y)	1.78
Sortino ratio (5Y)	0.75
Volume	368.6K
Weekly RSI	56.45
YTD price change	170.1%
YTD total return	170.1%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	64.1M
Float percentage	69.42%
Shares change (QoQ)	1.39%
Shares change (YoY)	20.98%
Shares held by insiders	14.91%
Shares held by institutions	9.03%
Shares outstanding	92.3M
Short % of float	5.38%
Short % of shares	3.73%
Short ratio	5.5 days

Deeper analysis on DRTS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DRTS report

Is a complete DRTS research report available?

No complete published report is available for Alpha Tau Medical Ltd. (DRTS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Alpha Tau Medical Ltd. (DRTS)

Price

Financial snapshot

Fair-value bridge

Latest news · DRTS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DRTS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DRTS

Frequently asked questions